Navigation

2007/005 NICE issues guidance on treating secondary hyperparathyroidism in patients with kidney disease

NICE has issued guidance on the use of cinacalcet in the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy.

Hyperparathyroidism is the excessive production of parathyroid hormone - a hormone which controls the levels of calcium and phosphate in the blood. Secondary hyperparathyroidism (when hyperparathyroidism is caused by another condition, such as kidney disease) is associated with bone disease and calcification of arteries and soft tissue, which can lead to other complications. Almost all people who need dialysis because of kidney disease have secondary hyperparathyroidism. Cinacalcet reduces the amount of parathyroid hormone produced, which also results in lower calcium and phosphate levels in the blood.

 

This page was last updated: 30 April 2009

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.